{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8"},{"groupId":"OG001","value":"42.1"}]}],"title":"72 hours - No pain [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5"},{"groupId":"OG001","value":"50.0"}]}],"title":"72 hours - Pain [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG001","value":"5.3"}]}],"title":"72 hours - Pain and winces [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG001","value":"2.6"}]}],"title":"72 hours - Pain, winces and withdraws [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1"},{"groupId":"OG001","value":"79.5"}]}],"title":"7 days - No pain [N=58, 39]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4"},{"groupId":"OG001","value":"20.5"}]}],"title":"7 days - Pain [N=58, 39]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"0.0"}]}],"title":"7 days - Pain and winces [N=58, 39]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"7 days - Pain, winces and withdraws [N=58, 39]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"The study physician assessed the most affected joint for tenderness on the following 4-point scale:\n\n* no pain;\n* participant states that \"there is pain;\n* participant states \"there is pain and winces\";\n* participant states \"there is pain, winces and withdraws\" on palpation or passive movement of the affected study joint.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","groups":[{"description":"Participants who received canakinumab 150 mg in the core study and who were re-treated with canakinumab 150 mg for new flares during the overall 72 weeks. Data are reported for the last post-baseline flare for participants in this arm.","id":"OG000","title":"Re-treated With Canakinumab 150 mg"},{"description":"Participants who received triamcinolone acetonide (triam) 40 mg in the core study and who were switched to canakinumab 150 mg for treatment of new flares in extension study 2. Data are reported for the first post-baseline flare treated with canakinumab.","id":"OG001","title":"Triam Switched to Canakinumab"}],"paramType":"NUMBER","populationDescription":"Modified Analysis Set (MAS) consisting of all FAS patients who were either re-treated or switched to canakinumab during the 72 weeks. At each timepoint only patients with a value at both baseline flare and the new flare are included.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose and 7 days post dose for the last post-baseline flare for the canakinumab re-treated arm and for the first post-baseline flare treated with canakinumab in the triamcinolone acetonide arm during the overall 72 weeks.","title":"Physician's Assessment of Joint Tenderness for Participants Re-treated or Switched to Canakinumab","type":"SECONDARY","unitOfMeasure":"percentage of participants"}